Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy.

@article{Bahr2012LongtermCI,
  title={Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy.},
  author={Lena von Bahr and Berit Sundberg and Lena L{\"o}nnies and Birgitta Sander and Holger Karbach and Hans H{\"a}gglund and Per Ljungman and Britt Gustafsson and Helen Karlsson and Katarina le Blanc and Olle Ringd{\'e}n},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2012},
  volume={18 4},
  pages={557-64}
}
Thirty-one patients treated with mesenchymal stromal cells (MSCs) for acute graft-versus-host disease (aGVHD) or hemorrhagic cystitis between 2002 and 2007 were followed to investigate predictors of outcome, immunologic effects in vivo, and long-term survival. There was no correlation between in vitro suppression by MSCs in mixed lymphocyte cultures and outcome. Soluble IL-2 receptors were measured in blood before and after MSC infusion and declined significantly during the first week after MSC… CONTINUE READING
83 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 83 extracted citations

Similar Papers

Loading similar papers…